{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sama IE"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["821-833"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7319432"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(5)"],"pubmed_abstract":["<h4>Aims</h4>Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.<h4>Methods and results</h4>We performed a biological physical protein-protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein-protei"],"journal":["European journal of heart failure"],"pubmed_title":["A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure."],"pmcid":["PMC7319432"],"funding_grant_id":["NF-SI-0611-10170"],"pubmed_authors":["Nauta JF","Ter Maaten JM","Zannad F","Cleland JGF","Metra M","van der Meer P","Sama IE","Hillege HL","Lang CC","Samani NJ","Voors AA","Romaine SPR","Dickstein K","Anker SD","Lam CSP","Woolley RJ","Tromp J","Ng LL","van Veldhuisen DJ"],"additional_accession":[]},"is_claimable":false,"name":"A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.","description":"<h4>Aims</h4>Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.<h4>Methods and results</h4>We performed a biological physical protein-protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein-protei","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-22T06:39:56.072Z","creation":"2020-07-03T07:08:32Z"},"accession":"S-EPMC7319432","cross_references":{"pubmed":["32243695"],"doi":["10.1002/ejhf.1811"]}}